Skip to content
Annika Bansal – Lifestyle
Author:
Electra Therapeutics, Inc.
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
September 17, 2026
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
September 10, 2026
Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
September 9, 2026